%0 Journal Article
%T Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
%A Hajime Izumiyama
%A Isao Minami
%A Koshi Hashimoto
%A Masahiro Asakawa
%A Masahiro Terashima
%A Masanori Murakami
%A Ryotaro Bouchi
%A Takanobu Yoshimoto
%A Takato Takeuchi
%A Tatsuya Fukuda
%A Yoshihiro Ogawa
%A Yujiro Nakano
%A Yuriko Sasahara
%J Archive of "Cardiovascular Diabetology".
%D 2017
%R 10.1186/s12933-017-0516-8
%X Accumulation of epicardial fat (EF) is associated with increased cardio-metabolic risks and coronary events, independently of traditional cardiovascular risk factors. Therefore, the reduction of EF volume (EFV) may be associated with reduced cardio-metabolic risks and future cardiovascular events. Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce body fat including visceral fat and cardiovascular events in patients with type 2 diabetes. However, it has still been unknown whether SGLT2 inhibitors can reduce EFV
%K Luseogiflozin
%K Epicardial fat
%K Type 2 diabetes
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335851/